Clinical Expert Consensus Statements written by VASCERN

VASCERN Hereditary Haemorrhagic Telangiectasia (HHT) Statement on COVID-19 (March 2020)

Consensus statement of the VASCERN HTAD Working Group (January 23, 2019): 

In patients with HTAD, Fluoroquinolones should be used with caution because of a possible risk for exacerbation of aortic disease.  The use of alternatives is preferred while awaiting further evidence.

Consensus statement for the screening and management of patients with pathogenic ACTA2 variants (November 21, 2019)

Ingrid M. B. H. van de Laar, Eloisa Arbustini, Bart Loeys, Erik Björck, Lise Murphy, Maarten Groenink, Marlies Kempers, Janneke Timmermans, Jolien Roos-Hesselink, Kalman Benke, Guglielmina Pepe, Barbara Mulder, Zoltan Szabolcs, Gisela Teixidó-Turà, Leema Robert, Yaso Emmanuel, Arturo Evangelista, Alessandro Pini, Yskert von Kodolitsch, Guillaume Jondeau, Julie De Backer European reference network for rare vascular diseases (VASCERN) consensus statement for the screening and management of patients with pathogenic ACTA2 variants. Orphanet J Rare Dis14, 264 (2019) doi:10.1186/s13023-019-1186-2

VASCERN Heritable Thoracic Aortic Diseases (HTAD) Working Group statement on COVID-19 (March 2020)

This statement can equally be found in:

DutchVASCERN HTAD verklaring over Covid 19

FrenchDéclaration du groupe de travail VASCERN sur les maladies aortiques thoraciques héréditaires (HTAD) sur COVID-19

GermanVASCERN Erklärung zu Covid 19

MalteseStqarrija mill-VASCERN HTAD WG dwar il-COVID-19

Spanish: Declaración de VASCERN HTAD sobre Covid 19

VASCERN Medium-Sized Arteries (MSA) Working Group statement on COVID-19 (March 2020)

The MSA WG is currently working on the production of other consensus statement documents on various topics such as in vitro fertilization (IVF) and preimplantation genetic diagnosis (PGD) in vEDS.

The PPL-WG is currently working on the production of consensus statement documents on various topics including diagnostic patient pathway for PPL, QoL for children, compression in children.

VASCERN Vascular Anomalies (VASCA) Working Group COVID-19 Statement (March 20, 2020)– initiated by the patient advocacy groups in Europe and the United States and their medical advisory teams and approved by the VASCA WG.

This statement can equally be found in:

FrenchInformation COVID-19 pour les patients porteurs d’ Anomalies Vasculaires et/ou Lymphatiques

FinnishVASCERN Suonipoikkeavuuksien (VASCA) työryhmä – Tietoa koronaviruksesta (COVID-19) potilaille, joilla on vaikea suonipoikkeavuus

The VASCA-WG is currently working on creating other expert consensus statement documents on various rare vascular anomalies.

Comments are closed